



## Appendix 4D

---

Name of entity

**Corum Group Limited**

ABN or equivalent company reference

**25 000 091 305**

Half year ended ('current period')

**31 December 2022**

Financial year ended  
(‘previous corresponding period for  
Balance Sheet’)

**30 June 2022**

Half year ended  
(‘previous corresponding period for  
Statement of Comprehensive Income and  
Cash Flow Statement’)

**31 December 2021**



**CORUM GROUP LIMITED**  
ABN 25 000 091 305  
AND ITS CONTROLLED ENTITIES

## Results for announcement to the market

---

Extracts from this report for announcement to the market

1. Revenue from ordinary activities	Up 0.3% to	\$6,122,000
2. Profit from ordinary activities after tax attributable to members	Down 748.9% to	\$(571,000)
3. Profit for the period attributable to members	Down 756.3% to	\$(571,000)

Statement regarding dividends	No dividends have been declared
Record date for determining entitlements to the dividend	N/A

	Current Period 31 December 2022	Previous Corresponding Period 30 June 2022
Net tangible assets/(liabilities) per security (excluding intangible assets)	0.35 cents	0.42 cents



**Corum  
Group**

# **HALF-YEARLY REPORT FOR THE 6 MONTHS ENDED**

**31 December 2022**

**Corum Group Limited  
ABN 25 000 091 305**



## Contents

	<i>Page</i>
Directors' Report	2
Auditor's Independence Declaration	5
Consolidated Statement of Profit or Loss and Other Comprehensive Income	6
Consolidated Statement of Financial Position	7
Consolidated Statement of Changes in Equity	8
Consolidated Statement of Cash Flows	9
Notes to the Consolidated Financial Statements	10
Directors' Declaration	17
Independent Auditor's Review Report	18

## Directors' Report

The Directors present their report, together with the financial statements, on the Consolidated Entity consisting of Corum Group Limited ('Group', or 'Corum', or the 'Company') and the entities it controlled for the half-year ended 31 December 2022.

### Directors

The following were directors of Corum Group Limited since the beginning of the half-year and up to the date of this report, unless a different period is stated below:

Nick England	Executive Chairman and Interim CEO
Jon Newbery	Non-executive Director
Jayne Shaw	Non-executive Director
Dennis Bastas	Non-executive Director

### Company Secretary

Eryl Baron

### Principal Activities

Corum Group Limited (ASX:COO) is a technology and software development business. The key business activities relate to:

- Health Services – which involves the development and distribution of business software (point-of-sale, pharmaceutical dispensing, multi-site retail management and cyber security) and associated support services and computer hardware for the pharmacy industry. In addition, Health Services includes PharmX, which owns, develops and manages the industry leading electronic ordering gateway, as well as PharmXchange, a newly launched online ordering platform initially focussed on the pharmacy industry and integrated with PharmX.
- Corum eCommerce (prior year only) - which involved the operation of a payment gateway primarily for the real estate sector. This segment was disposed of during the prior financial year.

### Operating Results

Revenue from continuing operations for the half-year was \$6,122,000, in line with the prior period (half-year ended 31 December 2021: \$6,101,000).

The loss before tax from continuing operations was \$434,000 (half-year ended 31 December 2021: profit of \$349,000).

This result includes \$1,214,000 of non-recurring legal costs relating to the ongoing dispute between Fred IT Group Pty Ltd ('Fred IT') and PharmX Pty Ltd ('PharmX') and advisory costs. Excluding these non-recurring costs, the underlying operating profit before tax was \$780,000. There are no further costs related to the case with Fred IT expected. As previously announced, the hearing is completed and all submissions have been made. Final court judgement is expected in the first half of calendar year 2023.

Restructuring changes made in the second half of the previous financial year have resulted in a reduction in staffing costs of 10% in the half. There continues to be a disciplined approach to cost control balancing the need to invest in revenue generating initiatives with the growth in actual revenue.

A comprehensive review of our general IT costs has led to savings in communication, cloud and technology costs compared with the same period in the previous financial year. There have also been savings in various licence and technology costs where more efficient processes and resources have been implemented.

## **Directors' Report** continued

### **Operating Results** continued

The cost of amortisation of software development has increased in the current half-year compared to the prior period, with the acceleration of the amortisation of some of the older software products and the ongoing amortisation of the costs incurred in the development of Corum Clear Dispense.

The net loss after income tax for the half-year ended 31 December 2022 was \$571,000 (half-year ended 31 December 2021: profit of \$87,000).

### **Dividends**

No dividend was paid by the Company in the half-year ended 31 December 2022.

### **Review of Operations**

During this period the progress in PharmX has continued with year-to-date growth of 10% in the total number of supplier-to-pharmacy connections. This growth has mainly been driven by account matching exercises that ensure onboarding and connections between new suppliers and pharmacies is more automated and seamless. As at 31 December 2022, there are over 50,000 connections between suppliers and pharmacies. This increase will continue to drive revenue growth in future periods.

To ensure the ongoing reliability of the PharmX gateway we have recently transitioned the platform to the Cloud. This transition will provide more flexibility, system redundancy and improved monitoring and security and has been achieved with no downtime or interruption of service for customers. In addition, there has been ongoing development to enhance the functionality of the PharmX platform.

PharmXchange was successfully launched in June 2022 and has gained outstanding traction to date. PharmXchange is a digital sales and marketing solution for suppliers to the pharmacy industry and improves procurement efficiency in pharmacies. It is fully integrated with PharmX to enable electronic ordering and invoicing and allow suppliers to take advantage of the PharmX messaging functionality without requiring a full PharmX integration. There has been continued development of the platform during the past 6 months to improve functionality and useability. There are now over 1,200 pharmacies registered to use PharmXchange and over 30 suppliers live or in provisioning on the platform representing over 130 brands and over 7,000 products. These suppliers include such names as Haleon (previously GlaxoSmithKline), Arrotex, Revlon, Blackmores and Phillip Morris.

The new Cloud-based point-of-sale solution was also launched in a pilot store during the half-year. This has been released initially in a non-pharmacy site which has allowed Corum to expand outside the pharmacy market and facilitates testing to be undertaken in a less complex industry. After the completion of the pilot program, continued development is planned in preparation for release into the pharmacy sector.

Development has also continued during the current half-year on the Corum Clear suite of products. Conformance was achieved for the latest iteration of e-Prescribing requirements, including Healthcare Identifier (HI) and Active Script List. These were significant Government regulatory changes and the development ensures the software will remain compliant for our pharmacy customers.

### **Outlook**

In the immediate to medium term, Corum is focusing on growth through PharmX and PharmXchange. The PharmXchange business model resonates with both pharmacies and suppliers and driving traffic and users to the platform will continue to be a major focus. This will be achieved by accelerating supplier onboarding driven by marketing and promotional campaigns. We will continue to actively develop functionality and enhance the platform with richer feature sets planned for release in the coming 12 months.

## Directors' Report continued

### Outlook continued

We will also continue development of the existing PharmX platform following the recent transition to the cloud. To ensure the long-term stability and relevance of the platform, we are continuously improving and evolving PharmX to meet the needs and requirements of pharmacies, point-of-sale software vendors and suppliers.

To augment our organic growth initiatives, TMT Partners remain engaged as corporate advisors to actively seek M&A opportunities. Interesting opportunities continue to be identified and we are pursuing those that make strategic and commercial sense.

### Financial Position

The Consolidated Entity net assets are \$22,675,000 (June 2022: \$23,203,000). Working capital, current assets less current liabilities, is a surplus of \$3,156,000 (June 2022: \$3,472,000).

The cash position was \$5,235,000 (30 June 2022: \$5,759,000), a decrease of \$524,000 during the period. Operating cashflows excluding net tax refund were \$150,000. Excluding one-off legal and advisory cash payments of \$1,319,000, underlying operating cashflows for the half were \$1,469,000. As in previous years, the overall cash position benefited from a tax refund (including research and development incentive) of \$1.55 million that was received in the period (\$1.55 million in the half-year ended 31 December 2021). These inflows have been partly offset by the ongoing investment in new product development during the period of \$2.0 million (\$2.2 million in the half-year ended 31 December 2021).

### Going Concern

Directors have prepared these financial statements on the basis that the Company is a going concern.

### Events Subsequent to Reporting Date

No matters or circumstances have arisen since 31 December 2022 that have significantly affected, or may significantly affect the Group's operations, the results of those operations, or the Group's state of affairs in future financial years.

### Auditor's Independence Declaration

The auditor's independence declaration as required by section 307C of the Corporations Act 2001 is set out on page 5.

### Rounding of Amounts

The Company is an entity to which ASIC legislative instrument 2016/191 applies and, accordingly, amounts in the financial statements have been rounded to the nearest thousand dollars unless otherwise stated.

This Report of the Directors is signed in Sydney in accordance with a resolution of the Board of Directors.



**Nick England**  
Chairman



**Jon Newbery**  
Director

Dated: 24 February 2023

## Auditor's Independence Declaration

### DECLARATION OF INDEPENDENCE BY LEAH RUSSELL TO THE DIRECTORS OF CORUM GROUP LIMITED

As lead auditor for the review of Corum Group Limited for the half-year ended 31 December 2022, I declare that, to the best of my knowledge and belief, there have been:

1. No contraventions of the auditor independence requirements of the *Corporations Act 2001* in relation to the review; and
2. No contraventions of any applicable code of professional conduct in relation to the review.

This declaration is in respect of Corum Group Limited and the entities it controlled during the period.



Leah Russell  
Director

**BDO Audit Pty Ltd**

Sydney, 24 February 2023



**Consolidated Statement of Profit or Loss and Other Comprehensive Income  
for the half-year ended 31 December 2022**

	Note	31 December 2022 \$'000	31 December 2021 \$'000
<b>Revenue from continuing operations</b>	2	<b>6,122</b>	<b>6,101</b>
<b>Expenses related to continuing operations</b>			
Materials and consumables		(811)	(828)
Marketing		(100)	(135)
Employee benefits	3	(2,791)	(3,098)
Share-based payments		(43)	(37)
Technology, communication and cloud costs		(327)	(466)
Legal		(1,123)	(334)
Consulting		(122)	-
Depreciation and amortisation	3	(1,254)	(996)
Finance costs		(49)	(40)
Research and development tax benefit		190	207
Other		(126)	(25)
<b>(Loss) / profit from continuing operations before income tax</b>		<b>(434)</b>	<b>349</b>
Income tax expense	4	(137)	(261)
<b>(Loss) / profit from continuing operations</b>		<b>(571)</b>	<b>88</b>
Loss from discontinued operations		-	(1)
<b>Net (loss) / profit after tax for the half-year</b>		<b>(571)</b>	<b>87</b>
Other comprehensive income for the half-year, net of tax		-	-
<b>Total comprehensive income / (loss) for the half-year attributable to the owners of Corum Group Limited</b>		<b>(571)</b>	<b>87</b>
<b>Earnings per share</b>	5	<b>Cents</b>	<b>Cents</b>
<b>Basic earnings per share</b>		<b>(0.10)</b>	<b>0.01</b>
<b>Diluted earnings per share</b>		<b>(0.10)</b>	<b>0.01</b>

The consolidated statement of profit or loss and other comprehensive income should be read in conjunction with the accompanying notes.

## Consolidated Statement of Financial Position as at 31 December 2022

		31 December 2022 \$'000	30 June 2022 \$'000
<b>Assets</b>			
<b>Current assets</b>			
Cash and cash equivalents		5,235	5,759
Trade and other receivables	8	1,261	1,085
Inventories		13	42
Income tax receivable		875	1,549
Other assets		414	151
		<b>7,798</b>	<b>8,586</b>
<b>Non-current assets</b>			
Property, plant and equipment		217	291
Right of use assets		165	312
Intangibles	9	20,613	20,725
Deferred tax assets		579	707
Security deposits		-	148
		<b>21,574</b>	<b>22,183</b>
<b>Total Assets</b>		<b>29,372</b>	<b>30,769</b>
<b>Liabilities</b>			
<b>Current liabilities</b>			
Trade and other payables		3,561	3,828
Provisions		773	900
Lease liability		176	303
Deferred revenue		132	83
		<b>4,642</b>	<b>5,114</b>
<b>Non-current liabilities</b>			
Other payables		961	1,305
Provisions		111	106
Lease liability		-	23
Deferred tax liability		983	1,018
		<b>2,055</b>	<b>2,452</b>
<b>Total liabilities</b>		<b>6,697</b>	<b>7,566</b>
<b>Net assets</b>		<b>22,675</b>	<b>23,203</b>
<b>Equity</b>			
Issued capital	10	98,405	98,366
Reserves		43	39
Accumulated losses		(75,773)	(75,202)
<b>Total Equity</b>		<b>22,675</b>	<b>23,203</b>

The consolidated statement of financial position should be read in conjunction with the accompanying notes.

**Consolidated Statement of Changes in Equity for the half-year ended  
31 December 2022**

	Note	Issued capital \$'000	Share-based Payments Reserve \$'000	Accumulated losses \$'000	Total equity \$'000
<b>Balance at 1 July 2022</b>		<b>98,366</b>	<b>39</b>	<b>(75,202)</b>	<b>23,203</b>
Loss after income tax		-	-	(571)	(571)
Performance rights exercised	10	39	(39)	-	-
Performance rights issued and current year expense		-	43	-	43
<b>Balance at 31 December 2022</b>		<b>98,405</b>	<b>43</b>	<b>(75,773)</b>	<b>22,675</b>
<b>Balance at 1 July 2021</b>		<b>98,366</b>	<b>18</b>	<b>(75,454)</b>	<b>22,930</b>
Profit after income tax		-	-	87	87
Performance rights issued		-	37	-	37
<b>Balance at 31 December 2021</b>		<b>98,366</b>	<b>55</b>	<b>(75,367)</b>	<b>23,054</b>

The consolidated statement of changes in equity should be read in conjunction with the accompanying notes.

**Consolidated Statement of Cash Flows for the half-year ended  
31 December 2022**

	<b>31 December 2022 \$'000</b>	<b>31 December 2021 \$'000</b>
<b>Cash flows from operating activities</b>		
Receipts from customers	6,587	6,682
Payments to suppliers and employees	(6,474)	(5,990)
Interest and other revenue received	37	13
Research and development incentive received net of income tax paid	1,550	1,554
Cashflows from discontinued operations	-	65
<b>Net cash from operating activities</b>	<b>1,700</b>	<b>2,324</b>
<b>Cash flows from investing activities</b>		
Payments for property, plant and equipment	(49)	(62)
Payments for intangible assets	(1,998)	(2,199)
Cashflows from discontinued operations	-	25
<b>Net cash used in investing activities</b>	<b>(2,047)</b>	<b>(2,236)</b>
<b>Cash flows from financing activities</b>		
Principal paid on lease liabilities	(169)	(169)
Interest paid on lease liabilities	(8)	(16)
<b>Net cash used in financing activities</b>	<b>(177)</b>	<b>(185)</b>
<b>Net decrease in cash and cash equivalents</b>	<b>(524)</b>	<b>(97)</b>
Cash and cash equivalents at beginning of the period	5,759	6,478
<b>Cash and cash equivalents at end of the period</b>	<b>5,235</b>	<b>6,381</b>

The consolidated statement of cash flows should be read in conjunction with the accompanying notes.

## **Notes to the Consolidated Financial Statements for the half-year ended 31 December 2022**

This financial report includes the consolidated financial statements and notes of Corum Group Limited and controlled entities ('Consolidated Entity', or 'Group', or 'Corum', or the 'Company'). Corum Group Limited is a listed public company, incorporated and domiciled in Australia.

The presentational and functional currency is Australian dollars.

### **Note 1: Basis of preparation**

#### **a) Basis of preparation**

The half-year consolidated financial statements have been prepared in accordance with the requirements of the Corporations Act 2001, Australian Accounting Standard AASB 134: Interim Financial Reporting, Australian Accounting Interpretations and other authoritative pronouncements of the Australian Accounting Standards Board.

It is recommended that the half-year financial report be read in conjunction with the Annual Financial Report for the year ended 30 June 2022 and any public announcements made by Corum during the half-year in accordance with continuous disclosure requirements arising under the Corporations Act 2001.

The half-year financial statements have been prepared using the same accounting policies consistently applied by the entities in the Consolidated Entity as used in the annual financial statements for the year ended 30 June 2022.

The half-year financial report does not include full disclosure of the type normally included in an annual financial report.

#### **b) Reporting basis and conventions**

The financial statements have been prepared on an accruals basis and are based on historical costs; modified where applicable by the measurement at fair value of selected non-current assets, financial assets and financial liabilities.

#### **c) Going concern basis**

The financial statements have been prepared on the going concern basis, which contemplates continuity of normal business activities and the realisation of assets and discharge of liabilities in the normal course of business.

#### **d) New, revised or amending Accounting Standards and Interpretations adopted**

The Consolidated Entity has adopted all the new, revised or amending Accounting Standards and Interpretations issued by the Australian Accounting Standards Board ('AASB') that are mandatory for the current reporting period.

There were no standards and amendments that applied for the first time that had an impact on the consolidated financial statements of the Consolidated Entity for the half-year reporting period commencing 1 July 2022.

Any new, revised or amending Accounting Standards or Interpretations that are not yet effective have not been adopted.

**Notes to the Consolidated Financial Statements  
for the half-year ended 31 December 2022**

	31 December 2022 \$'000	31 December 2021 \$'000
<b>Note 2: Revenue</b>		
<i>Sales revenue</i>		
Rendering of services	5,967	5,926
Sale of goods	118	162
	<b>6,085</b>	<b>6,088</b>
<i>Other revenue</i>		
Interest received	37	13
	<b>37</b>	<b>13</b>
<b>Total revenue from continuing operations</b>	<b>6,122</b>	<b>6,101</b>
Revenue from discontinued operations	-	616
<b>Total revenue</b>	<b>6,122</b>	<b>6,717</b>

**Note 3: Expenses**

<i>Employee benefits</i>		
Employee benefits expenses	3,894	4,478
Capitalised development costs	(1,103)	(1,001)
Less employee benefits expenses related to discontinued operations	-	(379)
<b>Total employee benefits from continuing operations</b>	<b>2,791</b>	<b>3,098</b>
<i>Depreciation and amortisation</i>		
Software development	981	752
Leased assets	167	173
Property, plant and equipment	106	156
Capitalised depreciation costs	-	(68)
Less depreciation related to discontinued operations	-	(17)
<b>Total depreciation and amortisation from continuing operations</b>	<b>1,254</b>	<b>996</b>

**Notes to the Consolidated Financial Statements  
for the half-year ended 31 December 2022**

	<b>31 December 2022 \$'000</b>	<b>31 December 2021 \$'000</b>
<b>Note 4: Income tax</b>		
<i>The major components of income tax expense are:</i>		
Current period income tax charge	44	309
Adjustment for current income tax of items credited directly to equity (amortisation of capital raising costs)	17	17
Adjustment for current income tax of previous year	(1)	(7)
Utilisation and reversal of temporary differences	77	(48)
Less income tax estimate related to discontinued operations	-	(10)
	<b>137</b>	<b>261</b>

The Group generated operating losses between 1997 and 2009 which resulted in substantial carried forward tax losses. These tax losses can be used as an offset against taxable income in accordance with the consolidated tax group rules. The utilisation of these losses is expected to be minimal due to the application of the available fraction which has been impacted by capital raises in recent years.

The potential future tax benefits arising from tax losses and temporary differences have been recognised as deferred tax assets only to the extent that:

- the Group is likely to derive future assessable income of a nature and amount sufficient to enable the benefits to be realised;
- no changes or proposed changes in legislation are likely to adversely affect the Group's ability to realise these benefits; and
- the Group is likely to continue to comply with the conditions for deductibility of losses imposed by tax legislation.

	<b>31 December 2022 \$'000</b>	<b>31 December 2021 \$'000</b>
<b>Note 5: Earnings per share ('EPS')</b>		
<i>Reconciliation of earnings:</i>		
(Loss) / profit after income tax attributable to owners of the Company	(571)	87
<b>Earnings used in the calculation of basic and diluted EPS</b>	<b>(571)</b>	<b>87</b>
	<b>Number</b>	<b>Number</b>
Weighted average number of ordinary shares used in calculating basic earnings per share	596,960,593	596,756,789
Weighted average number of ordinary shares used in calculating diluted earnings per share <sup>(i)</sup>	596,960,593	601,115,485

- (i) Potential ordinary shares are only treated as dilutive when they would decrease earnings per share.

## Notes to the Consolidated Financial Statements for the half-year ended 31 December 2022

### Note 6: Dividends paid and proposed

There were no dividends paid, recommended or declared during the current half-year or previous financial year or subsequent to the end of the current half-year.

### Note 7: Operating segments

#### *Identification of reportable operating segments*

The Group is organised into one operating segment: Health Services (prior year two operating segments: Health Services and eCommerce). These operating segments are based on internal reports reviewed and used by the Board of Directors (who are identified as the Chief Operating Decision Makers ('CODM')) in assessing performance and in determining the allocation of resources. Consideration is given to the nature and distinctiveness of the products or services sold, the manner in which they are provided and the organisational structure.

The CODM review profit/(loss) before income tax ('segment result'). The accounting policies adopted for reporting to the CODM are consistent with those adopted in the financial statements.

The Group operates predominantly in Australia.

#### *Types of services*

The principal services of each of these operating segments are as follows:

- Health Services – which involves the development and distribution of business software (point-of-sale, pharmaceutical dispensing, multi-site retail management and cyber security) and associated support services and computer hardware for the pharmacy industry. In addition, Health Services owns, develops and manages PharmX, the industry leading electronic ordering gateway, as well as PharmXchange, a newly launched online ordering platform initially focussed on the pharmacy industry and integrated with PharmX.
- Corum eCommerce (prior year only) - which involved the operation of a payment gateway primarily for the real estate sector. This segment was disposed of during the prior financial year.

#### *Intersegment transactions*

An internally determined transfer price is set for all inter-segment sales. This price is reset annually and is based on arm's length pricing. All such transactions are eliminated on consolidation.

Corporate charges are allocated to reporting segments based on the segments' overall proportion of revenue generation within the Group or estimates of the time individuals apply to each segment, which is representative of likely consumption of head office expenditure.

For the purpose of segment reporting and understanding segment performance, the net benefit of research and development tax incentives are disclosed in the segment to which they relate.



**Notes to the Consolidated Financial Statements  
for the half-year ended 31 December 2022**

**Note 7: Operating segments** continued

<i>Segment performance</i>	<b>Health Services \$'000</b>	<b>eCommerce<sup>(1)</sup> \$'000</b>	<b>Intersegment eliminations /unallocated \$'000</b>	<b>Consolidated \$'000</b>
<b>Half-year to 31 December 2022</b>				
<b>Revenue</b>				
Rendering of services	5,958	-	9	5,967
Sales of goods	118	-	-	118
Interest and other revenue	-	-	37	37
<b>Total revenue</b>	<b>6,076</b>	<b>-</b>	<b>46</b>	<b>6,122</b>
<b>Profit / (Loss) before income tax</b>				
<b>Expense</b>	<b>20</b>	<b>-</b>	<b>(454)</b>	<b>(434)</b>
Depreciation and amortisation of segment assets	1,237	-	17	1,254
<b>As at 31 December 2022</b>				
Total Assets	23,759	-	5,613	29,372
Total Liabilities	(5,602)	-	(1,095)	(6,697)
<b>Half-year to 31 December 2021</b>				
<b>Revenue</b>				
Rendering of services	5,926	616	-	6,542
Sales of goods	162	-	-	162
Interest and other revenue	-	-	13	13
<b>Total revenue</b>	<b>6,088</b>	<b>616</b>	<b>13</b>	<b>6,717</b>
<b>Profit / (Loss) before income tax</b>				
<b>Expense</b>	<b>545</b>	<b>9</b>	<b>(196)</b>	<b>358</b>
Depreciation and amortisation of segment assets	977	17	19	1,013
<b>As at 30 June 2022</b>				
Total Assets	23,258	-	7,511	30,769
Total Liabilities	(5,871)	-	(1,695)	(7,566)

(1) The eCommerce business was disposed of during the prior financial year.

**Notes to the Consolidated Financial Statements  
for the half-year ended 31 December 2022**

<b>Note 8: Current assets - trade and other receivables</b>	<b>31 December 2022 \$'000</b>	<b>30 June 2022 \$'000</b>
Trade receivables	1,227	1,086
Less: Allowance for expected credit loss	(40)	(60)
	<u>1,187</u>	<u>1,026</u>
Other receivables	74	59
<b>Total trade and other receivables</b>	<u><b>1,261</b></u>	<u><b>1,085</b></u>

<b>Note 9: Non-current assets - intangibles</b>	<b>31 December 2022 \$'000</b>	<b>30 June 2022 \$'000</b>
Goodwill – at cost	2,115	2,115
Accumulated impairment	-	-
	<u><b>2,115</b></u>	<u><b>2,115</b></u>
Software product development – at cost	27,696	26,098
Accumulated impairment	(1,467)	(1,467)
Research and development incentives	(8,277)	(7,548)
Accumulated amortisation	(3,387)	(2,543)
	<u><b>14,565</b></u>	<u><b>14,540</b></u>
Customer Contracts/Relationships – at cost	3,833	3,833
Accumulated amortisation	(639)	(502)
	<u><b>3,194</b></u>	<u><b>3,331</b></u>
PharmX brand – at cost	739	739
Accumulated impairment	-	-
	<u><b>739</b></u>	<u><b>739</b></u>
<b>Total intangible assets</b>	<u><b>20,613</b></u>	<u><b>20,725</b></u>

## Notes to the Consolidated Financial Statements for the half-year ended 31 December 2022

### Note 9: Non-current assets – intangibles continued

#### Reconciliation

Consolidated	Goodwill \$'000	Software product development \$'000	Brand \$'000	Customer Contracts/ Relationships \$'000	Total \$'000
<b>Balance at 1 July 2021</b>	<b>2,115</b>	<b>12,826</b>	<b>739</b>	<b>3,605</b>	<b>19,285</b>
Additions	-	4,487	-	-	4,487
Research and development incentives	-	(1,464)	-	-	(1,464)
Amortisation	-	(1,309)	-	(274)	(1,583)
<b>Balance at 30 June 2022</b>	<b>2,115</b>	<b>14,540</b>	<b>739</b>	<b>3,331</b>	<b>20,725</b>
Additions	-	1,598	-	-	1,598
Research and development incentives	-	(729)	-	-	(729)
Amortisation	-	(844)	-	(137)	(981)
<b>Balance at 31 December 2022</b>	<b>2,115</b>	<b>14,565</b>	<b>739</b>	<b>3,194</b>	<b>20,613</b>

Research and development tax benefits are offset against related software development costs when they are capitalised. The research and development tax benefit in the Consolidated Statement of Profit or Loss and Other Comprehensive Income is reduced accordingly.

Goodwill has been recognised on acquisition of PharmX in the year ended 30 June 2021.

### Note 10: Issued capital

Movement in ordinary share capital	Shares	\$'000
Balance at 1 July 2022	596,756,789	98,366
Performance rights exercised	625,000	39
<b>Balance at 31 December 2021</b>	<b>597,381,789</b>	<b>98,405</b>

### Note 11: Events after the reporting period

No matters or circumstances have arisen since 31 December 2022 that have significantly affected, or may significantly affect the Group's operations, the results of those operations, or the Group's state of affairs in future financial years.

## Directors' Declaration

In the opinion of the Directors of Corum Group Limited:

- (a) The financial statements and notes, set out on pages 6 to 16 are in accordance with the Corporations Act 2001, including:
  - (i) giving a true and fair view of the Consolidated Entity's financial position as at 31 December 2022 and of its performance for the half-year ended on that date; and
  - (ii) complying with Australian Accounting Standard AASB 134 'Interim Financial Reporting', the Corporations Regulations 2001 and other mandatory professional reporting requirements; and
- (b) There are reasonable grounds to believe that the Company will be able to pay its debts as and when they become due and payable.

Signed in accordance with a resolution of the Board of Directors made pursuant to section 303(5) of the Corporations Act 2001.

On behalf of the Board

A handwritten signature in black ink, appearing to read 'N. England'.

**Nick England**  
*Chairman*

A handwritten signature in black ink, appearing to read 'Jon Newbery'.

**Jon Newbery**  
*Director*

Dated: 24 February 2023

## INDEPENDENT AUDITOR'S REVIEW REPORT

To the members of Corum Group Limited,

### Report on the Half-Year Financial Report

#### Conclusion

We have reviewed the half-year financial report of Corum Group Limited (the Company) and its subsidiaries (the Group), which comprises the consolidated statement of financial position as at 31 December 2022, the consolidated statement of profit or loss and other comprehensive income, the consolidated statement of changes in equity and the consolidated statement of cash flows for the half-year ended on that date, a summary of statement of accounting policies and other explanatory information, and the directors' declaration.

Based on our review, which is not an audit, we have not become aware of any matter that makes us believe that the accompanying half-year financial report of the Group does not comply with the *Corporations Act 2001* including:

- (i) Giving a true and fair view of the Group's financial position as at 31 December 2022 and of its financial performance for the half-year ended on that date; and
- (ii) Complying with Accounting Standard AASB 134 *Interim Financial Reporting* and the *Corporations Regulations 2001*.

#### Basis for conclusion

We conducted our review in accordance with ASRE 2410 *Review of a Financial Report Performed by the Independent Auditor of the Entity*. Our responsibilities are further described in the *Auditor's Responsibilities for the Review of the Financial Report* section of our report. We are independent of the Company in accordance with the auditor independence requirements of the *Corporations Act 2001* and the ethical requirements of the Accounting Professional and Ethical Standards Board's APES 110 *Code of Ethics for Professional Accountants (including Independence Standards)* (the Code) that are relevant to the audit of the annual financial report in Australia. We have also fulfilled our other ethical responsibilities in accordance with the Code.

We confirm that the independence declaration required by the *Corporations Act 2001* which has been given to the directors of the Company, would be the same terms if given to the directors as at the time of this auditor's review report.

#### Responsibility of the directors for the financial report

The directors of the Company are responsible for the preparation of the half-year financial report that gives a true and fair view in accordance with Australian Accounting Standards and the *Corporations Act 2001* and for such internal control as the directors determine is necessary to enable the preparation of the half-year financial report that gives a true and fair view and is free from material misstatement, whether due to fraud or error.



### **Auditor's responsibility for the review of the financial report**

Our responsibility is to express a conclusion on the half-year financial report based on our review. ASRE 2410 requires us to conclude whether we have become aware of any matter that makes us believe that the half-year financial report is not in accordance with the *Corporations Act 2001* including giving a true and fair view of the Group's financial position as at 31 December 2022 and its financial performance for the half-year ended on that date and complying with Accounting Standard AASB 134 *Interim Financial Reporting* and the *Corporations Regulations 2001*.

A review of a half-year financial report consists of making enquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Australian Auditing Standards and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.

BDO  
BDO Australia Ltd  


**Leah Russell**

**Director**

Sydney, 24 February 2023

**CORUM GROUP LIMITED**

ABN 25 000 091 305

**Telephone** +61 2 8871 8501  
**[www.corumgroup.com.au](http://www.corumgroup.com.au)**

